4-(1H-咪唑-1-基甲基)苯腈 | 112809-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(1H-咪唑-1-基甲基)苯腈
• 英文名称: 4-(imidazol-1-ylmethyl)benzonitrile
• 英文别名: 4-(1-imidazolylmethyl)-benzonitrile；4-(1H-imidazol-1-ylmethyl)benzonitrile
• CAS: 112809-54-8
• 化学式: C₁₁H₉N₃
• mdl: MFCD08060525
• 分子量: 183.213
• InChiKey: LUSFCTSUDCCYLQ-UHFFFAOYSA-N

物化性质

• 熔点：
  102.5-103.5
• 沸点：
  398.0±25.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  41.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090
• 包装等级：
  III
• 危险类别：
  8,6.1
• 危险性防范说明：
  P304+P340,P310,P302+P352,P280,P305+P351+P338,P260
• 危险品运输编号：
  2923
• 危险性描述：
  H302,H312,H314,H332
• 储存条件：
  存于室温下，请密封并保持干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(Imidazol-1-ylmethyl)benzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Imidazol-1-ylmethyl)benzonitrile
CAS number: 112809-54-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H9N3
Molecular weight: 183.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(1H-咪唑-1-基甲基)苯腈 生成 4-[1-Cyclopentylidene-1-(1-imidazolyl)methyl]benzonitrile
  参考文献：
  名称：

  BOHLMANN, ROLF;STREHLKE, PETER;HENDERSON, DAVID;SCHNEIDER, MARTIN;NISHINO+

  摘要：

  DOI：
• 作为产物：
  描述：

  咪唑 、 对氰基溴化苄 在 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 生成 4-(1H-咪唑-1-基甲基)苯腈
  参考文献：
  名称：

  合成和生化评估一系列有效的基于苄基咪唑的化合物，这些化合物可能是酶复合物17α-羟化酶/ 17,20-裂合酶（P450（17alpha））的潜在抑制剂。

  摘要：

  细胞色素P-450酶17α-羟化酶/ 17,20-裂合酶（P450（17alpha））是激素依赖性癌症的潜在靶标。在这里，我们报告了一系列针对该酶的两个成分即17α-羟化酶（17α-OHase）和17,20-裂合酶（裂解酶）的基于苄基咪唑的化合物的合成和生化评估。 。生化测试的结果表明，合成的化合物是良好的抑制剂，与N-4-碘苄基咪唑（5）（针对17α-OHase的IC50 = 10.06 microM和针对裂解酶的IC50 = 1.58 microM）相比，与裂解酶相比，其对裂解酶的活性相等。标准化合物，酮康唑（KTZ）（针对17alpha-OHase的IC50 = 3.76 +/- 0.01 microM，针对裂解酶的IC50 = 1.66 +/- 0.15 microM）。此外，所测试的化合物对17α-OHase成分的效力较弱，

  DOI：

  10.1016/j.bmcl.2006.05.070
• 作为试剂：
  描述：

  cadmium(II) nitrate tetrhydrate 、 水 、 2,2',2'',2''',2'''',2'''''-(1,3,5-三嗪-2,4,6-三基三次氮基)六乙酸 在 4-(1H-咪唑-1-基甲基)苯腈 作用下， 反应 72.0h， 以60%的产率得到
  参考文献：
  名称：

  使用六羧酸构建的三种金属配合物的合成、结构和特性

  摘要：

  在本研究中，三种新的 3D 配位聚合物 (CPs)，{[Cd3(L)(H2O)6]·H2O}n (1)，{[Cu1.5(L)0.5(bimb)1.5]·5H2O·DMF }n (2) 和 {[Mn1.5(H3L)(bibp)0.5(H2O)2]·3H2O}n (3) (bimb= 1,3-双(咪唑-1-基)苯，bibp= 1,4-双（（4-咪唑-1-基）苄基）哌嗪），在溶剂热或水热条件下基于六齿配体（1,3,5-三嗪-2,4,6-三胺六-乙酸 (H6L))。通过红外光谱和单晶 X 射线衍射分析进行结构解析，而热重分析 (TGA)（动态和等温）和 XRD 技术用于聚合物的性能评估。此外，在室温下测试了 1 中 Fe3+ 离子的荧光性质和检测，本文还描述了 2 的电化学行为。

  DOI：

  10.3390/molecules24244431

文献信息

• Alpha-heterocyclc substituted tolunitriles
  申请人：Ciba-Geigy Corporation

  公开号：US04978672A1

  公开（公告）日：1990-12-18

  The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## wherein R and Ro represent hydrogen or lower alkyl; or R and Ro located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ring; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl, (lower alkyl, aryl or aryl-lower alkyl)-thio, lower alkenyl, aryl, aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl, or C.sub.3 -C.sub.6 -cycloalkyl-lower alkyl; or R.sub.1 and R.sub.2 combined represent lower alkylidene, mono- or di-aryl-lower alkylidene; R.sub.1 and R.sub.2 combined also represent C.sub.4 -C.sub.6 -straight chain alkylene, lower alkyl-substituted straight chain alkylene or ortho-phenylene bridged-C.sub.2 -C.sub.4 -straight chain alkylene, each forming with the carbon atom attached thereto a corresponding optionally substituted or benzo-fused 5, 6 or 7-membered ring; W represents 1-imidazolyl, 1-(1,2,4- or 1,3,4)-triazolyl or 3-pyridyl; or W represents 1-imidazolyl, 1-(1,2,4 or 1,3,4)-triazolyl or 3-pyridyl substituted by lower alkyl; and pharmaceutically acceptable salts thereof.

  该发明涉及式I的芳香化酶抑制化合物##STR1##其中R和Ro代表氢或较低的烷基；或R和Ro位于相邻的碳原子上，当与它们连接的苯环结合时形成萘或四氢萘环；R.sub.1和R.sub.2独立地代表氢、较低的烷基、(较低的烷基、芳基或芳基-较低的烷基)-硫、较低的烯基、芳基、芳基-较低的烷基、C.sub.3-C.sub.6-环烷基或C.sub.3-C.sub.6-环烷基-较低的烷基；或R.sub.1和R.sub.2结合代表较低的烷基亚甲基、单芳基或双芳基-较低的烷基亚甲基；R.sub.1和R.sub.2结合还代表C.sub.4-C.sub.6-直链烷基、较低的烷基取代的直链烷基或邻苯二甲基桥联的C.sub.2-C.sub.4-直链烷基，每个与其连接的碳原子形成相应的可选择取代或苯并5、6或7-成员环；W代表1-咪唑基、1-(1,2,4-或1,3,4)-三唑基或3-吡啶基；或W代表1-咪唑基、1-(1,2,4或1,3,4)-三唑基或3-吡啶基，其被较低的烷基取代；以及其药学上可接受的盐。
• [EN] USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES<br/>[FR] UTILISATION D'UN INHIBITEUR D'AROMATASE POUR LE TRAITEMENT DE L'HYPOGONADISME ET DE MALADIES APPARENTÉES
  申请人：NOVARTIS AG

  公开号：WO2013036562A1

  公开（公告）日：2013-03-14

  This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.

  本发明涉及一种使用芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈来提高睾酮水平并治疗低睾酮血症及相关疾病的方法。本发明进一步涉及在特定的剂量方案下，使用芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈来提高睾酮水平并治疗低睾酮血症及相关疾病的方法。本发明还涉及包含所述芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈的药物组合物，可选地与其他活性成分结合使用。此外，本发明还涉及包含所述药物组合物以及使用说明的试剂盒。
• Selective aromatase inhibiting compounds
  申请人：Oy; Orion-yhtyma

  公开号：US05703109A1

  公开（公告）日：1997-12-30

  New compounds of formula (I) wherein R.sub.1 is H, CH.sub.3, OCH.sub.3, NO.sub.2, NH.sub.2, CN, CF.sub.3, CHF.sub.2, CH.sub.2 F or halogen, R.sub.2 is a heterocyclyl radical selected from 1-imidazolyl, triazolyl, tetrazolyl, pyrazolyl, pyrimidinyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl, R.sub.3 is H or OH, R.sub.4 is H, R.sub.5 is H or OH; or R.sub.4 is H and R.sub.3 and R.sub.5 combined form a bond; or R.sub.3 is H and R.sub.4 and R.sub.5 combined form --(O); R.sub.6 is methylene, ethylene, --CHOH--, --CH.sub.2 --CHOH--, --CHOH--CH.sub.2 --, --CH--CH-- or --C(--O)--; or R.sub.4 is H and R.sub.5 and R.sub.6 combined is --CH-- or --CH--CH.sub.2 --; stereoisomers thereof and non-toxic pharmaceutically acceptable acid addition salts thereof exhibit selective aromatase inhibiting properties, compared with their desmolase inhibiting properties. The compounds of the invention are valuable in the treatment of estrogen dependent diseases, e.g. breast cancer or benign prostatic hyperplasia (BPH).

  式（I）的新化合物，其中R.sub.1为H，CH.sub.3，OCH.sub.3，NO.sub.2，NH.sub.2，CN，CF.sub.3，CHF.sub.2，CH.sub.2 F或卤素，R.sub.2为从1-咪唑基，三唑基，四唑基，吡唑基，嘧啶基，噁唑基，噻唑基，异噁唑基和异噻唑基中选择的杂环基，R.sub.3为H或OH，R.sub.4为H，R.sub.5为H或OH；或R.sub.4为H且R.sub.3和R.sub.5结合形成键；或R.sub.3为H且R.sub.4和R.sub.5结合形成--(O)；R.sub.6为亚甲基，乙烯基，--CHOH--，--CH.sub.2 --CHOH--，--CHOH--CH.sub.2 --，--CH--CH--或--C(--O)--；或R.sub.4为H且R.sub.5和R.sub.6结合为--CH--或--CH--CH.sub.2 --；其立体异构体和非毒性药学上可接受的酸盐表现出选择性芳香化酶抑制性能，与它们的去甲醇酶抑制性能相比。本发明的化合物在治疗依赖雌激素的疾病，如乳腺癌或良性前列腺增生（BPH）中具有价值。
• Process for producing 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile
  申请人：Wadhwa Kumar Lalit

  公开号：US20050209294A1

  公开（公告）日：2005-09-22

  The invention discloses an improved process for producing 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile of Formula (Structure 2), an intermediate used in the manufacture of 4,4′-[1H-1,2,4-triazol-1-ylmethylene] bisbenzonitrile (Letrozole), the process comprising of reacting salt of 1,2,4-triazole of Formula (Structure 4) with α-halo substituted tolunitrile of Formula (Structure 3) in presence of dimethylformamide, wherein the X represents alkali metals selected from a group of Li, Na, or K, preferably Na and Y represents a halogen group selected from Cl, Br or I, preferably Br.

  本发明公开了一种改进的4-(1H-1,2,4-三唑-1-基甲基)苯腈（结构式2）的制备过程，该中间体用于生产4,4′-[1H-1,2,4-三唑-1-亚甲基]双苯腈（来曲唑），该过程包括将1,2,4-三唑的盐（结构式4）与α-卤代取代的托卢腈（结构式3）在N,N-二甲基甲酰胺的存在下反应，其中X代表选自Li、Na或K的碱金属，优选Na，Y代表选自Cl、Br或I的卤素族，优选Br。
• [EN] PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS<br/>[FR] DÉRIVÉS PYRAZOLES OXADIAZOLES EN TANT QU'AGONISTES DE S1P1
  申请人：MERCK SERONO SA

  公开号：WO2010142628A1

  公开（公告）日：2010-12-16

  The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases. Wherein R1, R2 and R3 are as defined in the description.

  本发明涉及式(I)的吡唑噁二唑衍生物，以及它们用于治疗多发性硬化症和其他疾病的用途。其中R1、R2和R3如描述中所定义。